Promising new combo aims to tame rare lymphoma with fewer side effects

NCT ID NCT04745949

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated Jun 12, 2026 · Updated 24 times

Summary

This study tests a combination of targeted drugs and immunotherapy for people with untreated primary mediastinal large B-cell lymphoma (PMBL), a rare type of blood cancer. The treatment uses brentuximab vedotin (which delivers a toxin directly to cancer cells) and nivolumab (which helps the immune system attack the cancer), followed by a standard chemo-immunotherapy regimen. The goal is to see if this approach can control the disease effectively while being less harsh than standard chemotherapy alone. About 31 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE I PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.